Antibiotic-associated apoptotic enterocolitis in the absence of a defined pathogen: The role of intestinal microbiota depletion

Critical Care Medicine

Volumn 45, Issue 6, 2017, Pages e600-e606

  Wurm, Philipp ^a   Spindelboeck, Walter ^a   Krause, Robert ^a   Plank, Johannes ^a   Fuchs, Gottfried ^a   Bashir, Mina ^a   Petritsch, Wolfgang ^a   Halwachs, Bettina ^a,b   Langner, Cord ^a   Högenauer, Christoph ^a   Gorkiewicz, Gregor ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BIOTECHMED GRAZ   (Austria)

Author keywords

Antibiotic associated colitis; Epithelial apoptosis; Fecal microbiota transplantation; High volume diarrhea; Microbiota depletion

Indexed keywords

ANTIBIOTIC AGENT; DEXAMETHASONE; ELECTROLYTE SOLUTION; GLUCOCORTICOID; METHOTREXATE; PREDNISOLONE; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ADULT ONSET STILL DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC THERAPY; APOPTOSIS; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CRITICALLY ILL PATIENT; DIETARY INTAKE; DRUG WITHDRAWAL; ENTERIC FEEDING; ENTEROCOLITIS; FECES CULTURE; FEMALE; FLUID THERAPY; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HEAD INJURY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; INTESTINE FLORA; MALE; MULTIPLE ORGAN FAILURE; MULTIPLE TRAUMA; PATIENT TRANSPORT; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RHEUMATOID ARTHRITIS; STEROID THERAPY; SUPPLEMENTATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRAFFIC ACCIDENT; TREATMENT DURATION; VOMITING; CHEMICALLY INDUCED; DRUG EFFECTS; FECAL MICROBIOTA TRANSPLANTATION; MICROBIOLOGY; MIDDLE AGED; PROCEDURES;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ENTEROCOLITIS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; MIDDLE AGED;

EID: 85015877772     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002310     Document Type: Article

References (44)

1. Högenauer C, Hammer HF, Krejs GJ, et al: Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998; 27:702-710
2. Reintam Blaser A, Deane AM, Fruhwald S: Diarrhoea in the critically ill. Curr Opin Crit Care 2015; 21:142-153
3. Leffler DA, Lamont JT: Clostridium difficile infection. N Engl J Med 2015; 372:1539-1548
4. Högenauer C, Langner C, Beubler E, et al: Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006; 355:2418-2426
5. Gorkiewicz G: Nosocomial and antibiotic-associated diarrhoea caused by organisms other than Clostridium difficile. Int J Antimicrob Agents 2009; 33(Suppl 1):S37-S41
6. Krones E, Högenauer C: Diarrhea in the immunocompromised patient. Gastroenterol Clin North Am 2012; 41:677-701
7. Lai KK, Lamps LW: Enterocolitis in immunocompromised patients. Semin Diagn Pathol 2014; 31:176-191
8. Maynard CL, Elson CO, Hatton RD, et al: Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012; 489:231-241
9. Kump PK, Gröchenig HP, Lackner S, et al: Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013; 19:2155-2165
10. Lawley TD, Walker AW: Intestinal colonization resistance. Immunology 2013; 138:1-11
11. Hayakawa M, Asahara T, Henzan N, et al: Dramatic changes of the gut flora immediately after severe and sudden insults. Dig Dis Sci 2011; 56:2361-2365
12. Shimizu K, Ogura H, Goto M, et al: Altered gut flora and environment in patients with severe SIRS. J Trauma 2006; 60:126-133
13. Jackson MA, Goodrich JK, Maxan ME, et al: Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016; 65:749-756
14. Seto CT, Jeraldo P, Orenstein R, et al: Prolonged use of a proton pump inhibitor reduces microbial diversity: Implications for Clostridium difficile susceptibility. Microbiome 2014; 2:42
15. Freedberg DE, Toussaint NC, Chen SP, et al: Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: A crossover trial. Gastroenterology 2015; 149:883-885.e9
16. Lee SM, Donaldson GP, Mikulski Z, et al: Bacterial colonization factors control specificity and stability of the gut microbiota. Nature 2013; 501:426-429
17. Zaborin A, Smith D, Garfield K, et al: Membership and behavior of ultra-low-diversity pathogen communities present in the gut of humans during prolonged critical illness. MBio 2014; 5:e01361-e01314
18. Winter SE, Winter MG, Xavier MN, et al: Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 2013; 339:708-711
19. Harrison A, Bakaletz LO, Munson RS Jr: Haemophilus influenzae and oxidative stress. Front Cell Infect Microbiol 2012; 2:40
20. Morgun A, Dzutsev A, Dong X, et al: Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks. Gut 2015; 64:1732-1743
21. Chuang CH, Wang YH, Chang HJ, et al: Shanghai fever: A distinct Pseudomonas aeruginosa enteric disease. Gut 2014; 63:736-743
22. Luciano L, Hass R, Busche R, et al: Withdrawal of butyrate from the colonic mucosa triggers "mass apoptosis" primarily in the G0/G1 phase of the cell cycle. Cell Tissue Res 1996; 286:81-92
23. Hass R, Busche R, Luciano L, et al: Lack of butyrate is associated with induction of Bax and subsequent apoptosis in the proximal colon of guinea pig. Gastroenterology 1997; 112:875-881
24. Masia R, Peyton S, Lauwers GY, et al: Gastrointestinal biopsy findings of autoimmune enteropathy: A review of 25 cases. Am J Surg Pathol 2014; 38:1319-1329
25. Soldini D, Gaspert A, Montani M, et al: Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists. J Clin Pathol 2014; 67:582-586
26. Rieger K, Loddenkemper C, Maul J, et al: Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006; 107:1717-1723
27. Taur Y, Jenq RR, Perales MA, et al: The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124:1174-1182
28. Jenq RR, Ubeda C, Taur Y, et al: Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012; 209:903-911
29. van Nood E, Vrieze A, Nieuwdorp M, et al: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-415
30. Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20(Suppl 2):1-26
31. Kelly CR, Khoruts A, Staley C, et al: Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: A randomized trial. Ann Intern Med 2016; 165:609-616
32. Aroniadis OC, Brandt LJ, Greenberg A, et al: Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: A multicenter experience. J Clin Gastroenterol 2016; 50:398-402
33. Fischer M, Sipe BW, Rogers NA, et al: Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: Description of a protocol with high success rate. Aliment Pharmacol Ther 2015; 42:470-476
34. Agrawal M, Aroniadis OC, Brandt LJ, et al: The Long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 2016; 50:403-407
35. Lagier JC, Delord M, Million M, et al: Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route: A preliminary report. Eur J Clin Microbiol Infect Dis 2015; 34:1597-1601
36. Baxter M, Colville A: Adverse events in faecal microbiota transplant: A review of the literature. J Hosp Infect 2016; 92:117-127
37. Wang S, Xu M, Wang W, et al: Systematic review: Adverse events of fecal microbiota transplantation. PLoS One 2016; 11:e0161174
38. Kelly CR, Ihunnah C, Fischer M, et al: Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109:1065-1071
39. Baxter M, Ahmad T, Colville A, et al: Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis 2015; 61:136-137
40. Vermeire S, Joossens M, Verbeke K, et al: Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis 2016; 10:387-394
41. Kump P, Högenauer C: Any future for fecal microbiota transplantation as treatment strategy for inflammatory bowel diseases? Dig Dis 2016; 34(Suppl 1):74-81
42. Khoruts A, Rank KM, Newman KM, et al: Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2016; 14:1433-1438
43. Buffie CG, Bucci V, Stein RR, et al: Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015; 517:205-208
44. Li Q, Wang C, Tang C, et al: Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: A case report. Crit Care 2015; 19:37